Mitochondrial-derived peptide MOTS3 regulates metabolism and cell survival
US10391143B2 · kind B2 · utility
5Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 27, 2018 |
| Grant date | Aug 27, 2019 |
| Priority date | — |
| Expiry date | Aug 27, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.